Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01429441 · ClinicalTrials.gov registry record · Phase 3
Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole
A Phase 3 study, sponsored by ThromboGenics.
- Completed
- Registry status
- Phase 3
- Development phase
- 220
- Enrollment target
NCT01429441: Completed Phase 3 study, sponsored by ThromboGenics.
NCT01429441 is a Phase 3 study that has completed, run by ThromboGenics. The registered enrollment target is 220 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01429441, a Phase 3 study, has completed, sponsored by ThromboGenics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 220 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the treatment of symptomatic vitreomacular adhesion / (VMT) including macular hole with ocriplasmin.
Primary Outcome
Pharmacological VMA resolution without anatomical defect, based on SD-OCT and determined by the masked central reading center (CRC), with post-resolution vitrectomy considered as a failure. Missing data were imputed using the last observation carried forward (LOCF) method.
Interventions
- OTHER Sham injection
- DRUG Ocriplasmin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2011-10 |
| Est. Completion | 2014-10 |
| Phase | Phase 3 |
What the finished NCT01429441 record still lists
NCT01429441 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 2 interventions - of which Sham injection is the first listed.
NCT01429441 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01429441 about?
NCT01429441 is a clinical study titled "Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole". The purpose of this study is to evaluate the treatment of symptomatic vitreomacular adhesion / (VMT) including macular hole with ocriplasmin.
What is the current status of trial NCT01429441?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 220 participants. The study started on 2011-10. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01429441?
The interventions under investigation include: Sham injection (OTHER), Ocriplasmin (DRUG).
Who is sponsoring clinical trial NCT01429441?
This trial is sponsored by ThromboGenics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01429441's enrollment target sits among peer trials
220 1318th of 2000 higher than 672 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia